AI Article Synopsis

  • Reactive oxygen species (ROS) therapy faces challenges due to gap junction proteins, which help tumor cells expel harmful ROS and protect against oxidative damage.
  • The newly developed nanozyme, FePGOGA, combines oxidative polymerization, glucose oxidase, and GAP19 peptides to enhance ROS production and selectively starve tumor cells by degrading glucose.
  • In vivo studies reveal that FePGOGA significantly inhibits tumor growth under near-infrared light, showcasing its potential to overcome tumor resistance and improve the effectiveness of ROS-based therapies.

Article Abstract

Reactive oxygen species (ROS)-mediated tumor catalytic therapy is typically hindered by gap junction proteins that form cell-to-cell channels to remove cytotoxic ROS, thereby protecting tumor cells from oxidative damage. In this work, a multifunctional nanozyme, FePGOGA, is designed and prepared by Fe(III)-mediated oxidative polymerization (FeP), followed by glucose oxidase (GOx) and GAP19 peptides co-loading through electrostatic and π-π interactions. The FePGOGA nanozyme exhibits excellent cascade peroxidase- and glutathione-oxidase-like activities that efficiently catalyze hydrogen peroxide conversion to hydroxyl radicals and convert reduced glutathione to oxidized glutathione disulfide. The loaded GOx starves the tumors and aggravates tumor oxidative stress through glucose decomposition, while GAP19 peptides block the hemichannels by inducing degradation of Cx43, thus increasing the accumulation of intracellular ROS, and decreasing the transport of intracellular glucose. Furthermore, the ROS reacts with primary amines of heat shock proteins to destroy their structure and function, enabling tumor photothermal therapy at the widely sought-after mild temperature (mildPTT, ≤45 °C). In vivo experiments demonstrate the significant antitumor effectof FePGOGA on cal27 xenograft tumors under near-infrared light irradiation. This study demonstrates the successful ablation of gap junction proteins to overcome resistance to ROS-mediated therapy, providing a regulator to suppress tumor self-preservation during tumor starvation, catalytic therapy, and mildPTT.

Download full-text PDF

Source
http://dx.doi.org/10.1002/adma.202210464DOI Listing

Publication Analysis

Top Keywords

gap junction
12
ablation gap
8
photothermal therapy
8
catalytic therapy
8
junction proteins
8
gap19 peptides
8
tumor
6
therapy
5
junction protein
4
protein improves
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!